Background: Phase II studies have shown primary (neo-adjuvant) chemotherapy with bleomycin, ifosfamide and cisplatin (BIP) is active against inoperable cervical cancer. We present here results of a randomised phase III multicentre trial comparing radical radiotherapy with neo-adjuvant BIP chemotherapy followed by radical radiotherapy in patients with inoperable cervical cancer, designed to discover whether this combination might improve survival.
Introduction
The registration rate of cases of invasive cervical cancer in the UK is now falling, and five-year survival rates for patients with early stage disease treated with either surgery or radiotherapy are high (79%). However, the outlook is worse for women with either bulky pelvic or advanced stage disease (47% or 7%, respectively) [1] and the stage-specific five-year survival rates have remained unchanged over the past 25 years. Primary treatment in these cases relies on radiotherapy.
Treatment failure in these circumstances may result from sub-optimal treatment of pelvic disease and/or the existence of unrecognised metastatic disease outside the treatment fields. A number of other factors may increase the probability of local treatment failure. These include bulky tumours and radiotherapy dose reduction in the face of normal tissue damage. These problems have focussed attention on the potential role of neo-adjuvant (primary) chemotherapy.
Early studies in advanced and recurrent cervical cancer demonstrated complete and partial responses to both single-agent and combination chemotherapy regimes. However, response rates rarely exceeded 25% for single-agent and 50% for combination chemotherapy [2] [3] [4] . Among the most active single-agents are ifosfamide [5, 6] and cisplatin [7] , which exhibit synergistic activity in vitro [8] . Bleomycin has also shown singleagent activity [9] and the most effective combination regimens have been those combining cisplatin and bleomycin with other active agents [10, 11] . The combination of bleomycin, ifosfamide and cisplatin (BIP) is one of the most active against cervical cancer. In a multicentre phase II study of 49 patients with advanced or recurrent cervical cancer, treated with BIP, objective response was seen in 34 of 49 patients (69%) of which 10 (20%) were complete responses [12] with a median duration of response of 8 months. These results suggested a role for BIP in combination with radiotherapy in the management of primary disease. Such 'neo-adjuvant' chemotherapy might improve survival in bulky or advanced disease both by cytoreduction of the central tumour and eradication of extra-pelvic metastases. A randomised phase III multicentre trial comparing radical radiotherapy with 'neo-adjuvant' BIP chemotherapy followed by radical radiotherapy in cervical cancer deemed inoperable at examination under anaesthesia was carried out to confirm or refute these findings.
Patients and methods

Patient characteristics
Patients who had inoperable histologically proven cervical carcinoma with no disease spread to distant organs were eligible. Participating centres obtained approval from the appropriate local ethical committee and all patients gave fully informed consent before entering the trial. Exclusion criteria were as follows: previous treatment for invasive cervical cancer; small-cell cervical carcinoma; pregnancy; WHO performance status > 2; creatinine, or EDTA clearance < 50 ml/min or serum creatinine > 120 umol/1; WBC < 3.5 x 10 9 /l and/or platelets < 130 x 1O 9 /1; <0.2 probability of NOT developing severe encephalopathy with ifosfamide/mesna treatment, applying a predictive nomogram [13] ; severe pulmonary dysfunction or signs of respiratory insufficiency; other serious medical or psychological condition precluding treatment; expected survival < 3 months; history of second primary tumour other than basal cell carcinoma of the skin.
Randomisation
Patients were randomised to receive pelvic radiotherapy alone (RT) or BIP chemotherapy followed by pelvic radiotherapy (BIP + RT). The randomisation procedure was stratified by stage and radiotherapy centre. Randomisation sheets were prepared using the random permuted block method and maintained by staff at the CRC Trials Unit (CTU) in Birmingham. Patients were entered on-study by telephoning the CTU where eligibility criteria were checked and patients assigned to the next available treatment in strict order.
Radiotherapy
Clinicians were permitted to use any suitable radical combination of external beam and intra-cavitary radiotherapy. The radiation field sizes and doses were not prescribed in the protocol in the interests of maximising recruitment into the study. However, individual clinician's proposed treatment had to be outlined to the study co-ordinators and approved by the Radiotherapy Steering group before a patient could be entered into the study. In addition, clinicians were required to maintain a consistent radiotherapeutic approach for all subsequent trial patients irrespective of treatment allocation.
Chemotherapy
The BIP regimen has been described previously [12, 14] but in brief consisted of bleomycin 30 mg, ifosfamide 5 g/m 2 (given concurrently with Mesna 6 g/m 2 ) and cisplatin 50 mg/m 2 . The infusion of mesna was continued for 12 hours after ifosfamide administration in order to prevent serious and delayed urothelial toxicity. All patients were scheduled to receive two cycles of chemotherapy, prior to irradiation, unless there were any signs of tumour progression. A third cycle was permissible in responding patients if the measurable disease remained greater than 2 cm in diameter and a further response was expected. If the GFR measured <40 ml/min and/or the total WBC was below 3.0 x io y /l 28 days after chemotherapy, then doses of ifosfamide and cisplatin were reduced by 30%.
Investigations
Pre-treatment assessment included staging examination under anaesthesia with cystoscopy and sigmoidoscopy. Chest X-ray, ECG were performed as indicated. Abdomino-pelvic imaging was not obligatory and routine cross-sectional imaging to evaluate para-aortic lymph node enlargement was not performed pre-treatment. Haematological indices (full blood count and platelets), biochemical profile (urea, creatinine, liver function tests, albumin and magnesium) and creatinine or EDTA clearance were also measured. During treatment, full blood count and platelets were measured weekly and biochemical indices and performance status prior to each treatment cycle. Radiological and/or clinical assessment of tumour size was repeated prior to radiotherapy. Assessments of response, toxicity and performance status were made according to WHO criteria [15] . Assessments were made 12 weeks after radiotherapy then every 2 months until one year, threemonthly until 2 years, six-monthly until 5 years and annually thereafter.
Statistical methods
Data were collected prospectively and analysed on an intention-totreat basis. The analysis was performed using SAS statistical software (SAS Institute, SAS Circle, Cary, North Carolina, USA). The primary endpoints were survival and response. Survival was calculated from the date of randomisation to the date of death for patients who have died and until the date last confirmed alive, for those who are still alive. Survival curves were constructed using the method of Kaplan and Meier [16] and the log-rank test [17] was used to assess the differences between the treatment groups. Pearson's chi-square test was used to compare response rates and radiation toxicity (acute and chronic) across treatments. Secondary endpoints were toxicity due to chemotherapy (maximum severity for each toxicity across chemotherapy) and radiation toxicity (any reported toxicity during radiotherapy).
Results
Recruitment
One hundred seventy-seven women were randomised into this trial between June 1986 and June 1995 from hospitals throughout the UK. The majority of patients came from Birmingham, London and Nottingham who provided 42%, 24% and 9% of total recruitment, respectively. Five women were found to be ineligible after randomisation. Two patients, randomised to radiotherapy alone, were deemed ineligible because one had bilateral ovarian and pelvic metastases and the other had been previously treated for head and neck cancer. Three women randomised to BIP + RT were found to be ineligible as one had recurrent disease, another had small-cell carcinoma of the cervix and the third had been diagnosed with breast cancer seven years previously. These 5 women have been excluded from all analyses, leaving 86 women in each treatment group.
Protocol violations
There were five protocol violations, four occurring in the BIP + RT arm. One patient received radiotherapy prior to chemotherapy in error and another received five cycles of chemotherapy at her clinician's request. The creatinine clearance for three women (1 on RTand 2 on BIP + RT) was too low at randomisation, but all were subsequently treated, two with radiotherapy alone and the third with two cycles of BIP. These are included on an intention-to-treat basis.
Patient characteristics
Patient characteristics of the 172 eligible women are described in Table 1 and are well balanced across treatment arms. The median age of these women was 47 years, 44% were stage lib and 36% had poorly differentiated tumours.
Follow-up
Median follow-up for the 47 patients (26 on the RT arm and 21 in the BIP + RTarm) who are still alive is 9 years with a minimum follow-up of 3 years. The length of follow-up is balanced on both arms.
Clinical response
Response to all treatment is summarised in Table 2 and shows that 51 of 86 (59%) of the RT arm and 60 of 86 (69%) of patients receiving BIP + RT attained a complete or partial response. The difference of 10% between these response rates is not significant (x 2 = 2.06, P = 0.15). Response to chemotherapy alone, prior to radiotherapy, shows that only 5% of patients achieved a complete response and 45% had a partial response. Symptomatic improvement rates were better: 75% percent (48 of 64) of those presenting with vaginal bleeding, 65% (30 of 46) of those with vaginal discharge and 66% (22 of 33) of those with pain had experienced an improvement or complete resolution of symptoms by the end of chemotherapy, and in only one case did a patient report a worsening of their initial symptoms.
Survival
A total of 125 (73%) patients are known to have died; 60 (70%) on the RT arm and 65 (76%) of those having BIP + RT. One hundred fourteen (91%) women died of disease, three died as a result of the treatment, one died of cancer of the pancreas and seven died of other causes.
Median survival for all patients is 2 years (95% confidence interval (95% CI): 2-3 years) with an actuarial survival at 5 years of 32% (95% CI: 25%-39%). Survival curves for both treatment arms are shown in Figure 1 and illustrate that there is no significant evidence of a difference between the treatment groups; median survival is 2 years (95% CI: 1-3 years) for patients on the RTarm and 3 years (95% CI: 1-3 years) for those on the BIP + RTarm (/iog-rank = 0.11, P = 0.74).
Chemotherapy
In total, 190 cycles of chemotherapy were given, with 91% having at least 2 cycles. Three patients did not (18) receive any chemotherapy, two patients had one cycle of BIP, forty-eight recieved two cycles, twenty-nine were given three cycles and one patient had five cycles. Chemotherapy was delayed in nine patients (2 for administrative reasons, 3 due to leukopenia, 1 due to neutropenia, 2 due to risk of ifosfamide encephalopathy and 1 for reasons unknown). In 9 patients and 12 cycles of chemotherapy dosages were reduced because the patient was unfit for treatment at the full dose because of renal impairment and /or because the patient had a high risk of ifosfamideinduced encephalopathy. A further three patients received two cycles of chemotherapy when a third was indicated owing to low creatinine clearance in two cases and encephalopathy in the other.
Toxicity secondary to BIP chemotherapy
Chemotherapy toxicity was implicated in three deaths. One woman died of a septicaemia following the second cycle of BIP. Two others died from renal failure following their first cycle of chemotherapy but it is suspected disease progression may have played a role. Nineteen patients suffered an alteration of conscious level at some time during chemotherapy (3 grade 1, 14 grade 2 and 2 grade 3). There were 15 other patients who reported a maximum toxicity severity of 3 or 4 (excluding alopecia). These comprised mainly nausea and vomiting (13 cases) which was grade 4 in one case. Most of these patients were treated prior to the widespread availability of 5HT 3 antagonists. The other two cases were a grade 3 haematuria and grade 4 infection (Table 3) .
Acute and chronic radiotherapy toxicity
Details of the incidence of acute and chronic toxicity from radiotherapy are given in Table 4 . The addition of chemotherapy to the standard radiotherapy regimen did not appear to adversely affect tolerance to radiotherapy, in fact, significantly less acute (x 2 -13.9, P = 0.0002) and similar chronic toxicity (x 2 = 0.3, P = 0.56) was seen in the patients receiving neo-adjuvant chemotherapy. The reason for this is not clear. It could be a chance finding. Although we do not present here any data as to relative duration of radiotherapy course delivered, the reduced acute toxicity encountered provides no prima facie case to suspect delays may have been any more likely in those patients who received chemotherapy.
Discussion
The feasibility of giving neo-adjuvant chemotherapy together with radiotherapy, in the treatment of advanced cervical cancer, has been demonstrated in phase II studies [10-12, 18, 19] . The trial reported here was designed to evaluate whether the encouraging response rates seen with BIP would lead to improved survival and whether any such improvement could justify the additional toxicity experienced as a consequence of chemotherapy.
The interim results of this trial were presented at several meetings during the late 1980s with overall response (CR + PR) rates of 91% and 97% being reported in the chemotherapy and radiotherapy arms, respectively. Complete response was achieved in 75% of patients treated with BIP followed by radiotherapy as compared with only 56% of patients treated with radiotherapy alone [14] . Although there was no evidence to 
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8 (21) 5 (28) 3 (16) 5 (28) 5 (28) 15 (17) 5(33) 0(0) 4 (27) 3 (20) 0 (0) 3 (20) 0 (0) suggest that BIP was better than radiotherapy alone in terms of survival it was hoped that this improvement in complete response would translate into improved survival in the longer term. Regrettably, preliminary reports of interim data of the trial attracted widespread media interest that resulted in demands, from both patients and clinicians, for the new treatment off-study.
In some centres, this may have been exacerbated by the existence of six-week NHS waiting lists for radical radiotherapy. Accrual rates halved as a result and our attempts to reverse the downward trend in recruitment were unsuccessful. Consequently, this trial closed prematurely in December 1995 and it now seems unlikely that the value of neo-adjuvant BIP will ever be fully assessed.
It is disappointing that despite the early promise of phase II studies, no difference in survival was seen between the two arms of this trial. Recruitment was originally planned to be 300 patients, split equally between the treatment groups. Assuming the overall fiveyear survival rate for women with stage IIB, III and IVA disease to be 40%, these numbers give a 95% power to detect a difference between the groups in excess of 20%, at the 5% level. A difference of less than 20% was considered insufficient to justify the additional toxicity and prolongation of treatment resulting from the addition of neo-adjuvant chemotherapy to the existing standard radiotherapy regimen. Having only 88 patients in each arm, the chance of detecting this difference at the 5% significance level is reduced from 95% to 75%. During the study, BIP was generally well-tolerated and achieved rapid symptomatic relief so clinical opinion might now consider that a more modest difference, of say 15% would be sufficient to justify this chemotherapy. However, the power to detect such a difference with this number of patients is just 50% so it is clear that a clinically significant difference cannot be ruled out. A power of 95% to detect such a difference would require 280 patients in each arm.
Toxicity in this trial was significant but manageable in most cases and few patients needed discontinuation of treatment or dose reduction. It is, however, of note that three deaths were seen secondary to complications of treatment with chemotherapy. Disease progression may have played some role in two of these. Despite the acute toxicity, the majority of women had rapid improvement in disease-related symptoms if they were symptomatic at entry into the study. Our experience contrasts with that of Tay et al. [20] who reported 2 deaths in only 14 patients (with advanced or recurrent disease) treated with BIP. It seems likely that these difficulties reflect the composition of their small study group (11 of 14 had recurrent disease) as other authors have reported toxicity in line with our own experience [21, 22] . However, the experiences of Tay et al. [20] undoubtedly prompted considerable concerns amongst clinicians which may have had an adverse effect on accrual rates. Despite these concerns, this study shows that two to three cycles of BIP chemotherapy is welltolerated and could be justified, were a modest improvement in survival to exist.
To our knowledge, three other trials have been reported which show no survival benefit for neo-adjuvant chemotherapy. These include the study of Tattersall et al. which recruited 71 patients but also closed prematurely owing to poor accrual [23] . Interestingly, this study reported a higher incidence of pelvic relapse in patients receiving neo-adjuvant chemotherapy, and a higher incidence of metastatic relapse in the control radiotherapy-only arm. There was no significant difference, however, in overall survival. The second study published by the Asian Oceanian Clinical Oncology Association in 1995 recruited 260 patients, achieving its recruitment target [24] . Survival in this study was significantly lower in the neo-adjuvant arm suggesting that the delay in administration of radiotherapy may adversely affect survival. Thirdly, similar findings were reported by Souhami et al. [25] in 107 patients randomised to radiotherapy alone or 3 cycles of bleomycin, vincristine, mitomycin and cisplatin prior to radiotherapy. Whilst response rates were higher in the chemotherapy arm, toxicity was unacceptable and survival was reduced. These experiences, in conjunction with our own, raise important questions about the merits of allowing patients access to experimental treatments outside the confines of a clinical trial. The toxicity and expense of experi-mental treatment cannot be understated. Unless a new treatment has been shown to have proven clinical benefit there can be no justification for its use off-study. Only one randomised prospective study has reported a survival advantage with the use of neo-adjuvant chemotherapy in advanced cervical cancer. Sardi et al. [26] have reported a significant improvement in survival of patients, with stage IIIB carcinoma of the cervix, treated with combination vincristine, bleomycin and cisplatin prior to either surgery and irradiation or surgery radiotherapy alone. The obvious difference here is that all patients underwent surgery, and this approach clearly merits further consideration and investigation [4] .
Attention has focused recently on the use of concurrent cisplatin-based chemotherapy with radiotherapy. The results of three phase III randomised trials by Morris et al. [27] , Rose et al. [28] and Keys et al. [29] showed a significant reduction in the rate of cancer progression and longer disease-free survival for patients randomised to receive cisplatin based chemotherapy concurrently with radiotherapy. Each trial reported similar estimates of the relative risk of death (0.52 [27] , 0.58 [28] and 0.54 [29] ), in favour of the concurrent regimen. Preliminary results from two further studies by Whitney et al. [30] and Peters et al. [31] have also confirmed this finding (estimates of the relative risk of death being 0.72 [30] and 0.50 [31] ). These results prompted the National Cancer Institute to issue a clinical announcement [32] . They state that 'strong consideration should be given to the incorporation of concurrent cisplatin based chemotherapy with radiation therapy in women who require radiation therapy for treatment of cervical cancer'. Whether these results can be extrapolated to the UK setting is questionable due to the possible difference in the radiotherapy practice and subsequent dose-intensity between the USA and UK.
In summary, the results of this study do not show any survival benefit from the use of neo-adjuvant BIP chemotherapy in locally advanced cervical cancer. To date, there are no published studies with sufficient patient numbers to answer the wider question of whether neo-adjuvant chemotherapy is generally beneficial in these patients. This question may be answered by the forthcoming prospective overview of platinum-based neo-adjuvant chemotherapy in carcinoma of the cervix planned by the MRC Gynaecological Cancer Working Party. But perhaps the era of neo-adjuvant trials has been surpassed by the use of concurrent cisplatin-based chemoradiotherapy. However, it remains unclear as to which drugs or regimens are optimal within this setting.
